2 Nuclear Energy Stocks to Buy in May

The U.S. wants to quadruple nuclear capacity from about 100 GW in 2024 to 400 GW by 2050, supporting a strong outlook for nuclear suppliers and SMR developers. Cameco is highlighted as a major uranium beneficiary, producing about 17% of global uranium in 2024 and owning a 49% stake in Westinghouse, while NuScale is the only U.S. SMR designer with NRC approval. The article is broadly constructive on nuclear energy and AI-driven power demand, though it also notes NuScale still lacks a first firm commercial sale and remains about 80% below its recent high.

Analysis

The market is still underpricing the fact that the nuclear buildout is less a pure power-generation trade and more a constrained-inputs trade. In the near term, the scarce bottlenecks are conversion, enrichment, fuel fabrication, and qualified engineering labor — not reactor blueprints — which makes the supply-side winners much more durable than the design-only names. That favors CCJ over SMR on a 6-24 month horizon because pricing power should show up first in the fuel cycle, while SMR remains hostage to first-order execution risk and financing friction.

The second-order beneficiary is the broader industrial base around Westinghouse, EPC contractors, and grid interconnection providers, because any credible path to 400 GW requires permitting, transmission, and standardized procurement before it requires widespread commercial deployment. That creates a lagged trade: the headline narrative is AI-driven demand, but the actual cash flow bridge is likely government-backed contracting and long-duration fuel supply agreements. The implication is that the best risk-adjusted exposure is to companies monetizing scarcity or guaranteed demand, not to the highest beta “story stocks.”

The contrarian miss is that SMRs can be strategically important without being economically compelling for years; NRC approval is a necessary condition, not a commercialization catalyst. Investors may be extrapolating a policy tailwind into a revenue inflection that could still be 2-5 years away, especially if first-of-a-kind builds run over budget or require customer balance-sheet support. If that happens, SMR multiple compression could be severe even if the sector thesis remains intact.

For BAC, the opportunity is less about direct earnings and more about financing/underwriting optionality across the buildout. If project finance normalizes, large banks with infrastructure lending capability can quietly earn fees and collateralize the capex cycle, but that is a later-stage trade and not the cleanest immediate alpha.

Key Decisions for Investors

• Long CCJ vs short SMR for a 6-12 month relative-value trade: own the cash-flowing fuel bottleneck and fade commercialization risk; target 15-25% spread if uranium/contract pricing tightens.
• Add CCJ on pullbacks for a 12-24 month hold; the risk/reward favors a secular rerating if long-term supply contracts reprice, with downside cushioned by scarcity economics.
• Avoid chasing SMR into strength; if you want exposure, use defined-risk call spreads 12-24 months out to express optionality on first commercial wins while limiting downside to first-of-a-kind execution failures.
• Watch for a basket trade into EPC/industrial beneficiaries rather than pure-play reactor names; pair long industrials with short high-multiple pre-revenue nuclear equities if the market starts pricing the buildout too early.
• Use BAC only as a secondary beneficiary: buy on evidence of project finance syndication or DOE-backed deal flow, not on the headline alone; otherwise the catalyst is too delayed for near-term alpha.